Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

181. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS.

Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive-aged women. Apart from infertility, women with PCOS often have other endocrine disorders, including insulin resistance, hyperinsulinaemia and hyperandrogenism. Metformin,combined with clomiphene citrate (CC), has been shown to be more effective in ovulation induction when compared (...) with clomiphene citrate alone. The optimal duration for metformin pretreatment before initiation of clomiphene citrate, however, is unknown. OBJECTIVES: To determine the effectiveness of short-course (less than four weeks) metformin plus CC versus long-course (four weeks or more) metformin plus CC with regard to ovulation and achievement of pregnancy in infertile women with PCOS. SEARCH METHODS: We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, the Cochrane Central Register

Cochrane2012

182. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes.

Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22801704 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jul 17;157(2):JC2-13. doi: 10.7326/0003-4819-157-2-201207170-02013. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes. . Comment on [BMJ. 2012] PMID

Annals of Internal Medicine2012

183. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets 22584132 2012 06 22 2012 10 23 2016 12 15 1935-5548 35 7 2012 Jul Diabetes care Diabetes Care Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. 1446-54 10.2337/dc11-1928 We evaluated the addition of liraglutide to metformin (...) in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

184. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial 22413962 2012 04 19 2012 06 28 2015 11 19 1742-1241 66 5 2012 May International journal of clinical practice Int. J. Clin. Pract. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. 446-56 10.1111/j.1742-1241.2012.02911.x Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients (...) with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week trials in treatment-naïve patients to compare dapagliflozin plus metformin, dapagliflozin alone and metformin alone. Eligible patients had baseline HbA1c 7.5-12%. Each trial had three arms: dapagliflozin plus metformin, dapagliflozin monotherapy and metformin monotherapy. Dapagliflozin in combination and as monotherapy was dosed at 5 mg (Study 1) and 10 mg (Study 2). Metformin

EvidenceUpdates2012

185. Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial

Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial 22692637 2012 11 29 2013 06 04 2016 12 15 1525-1497 27 12 2012 Dec Journal of general internal medicine J Gen Intern Med Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. 1594-601 10.1007/s11606-012-2122-5 Adults at high risk for diabetes may have reduced health-related quality (...) of life (HRQoL). To assess changes in HRQoL after interventions aimed at diabetes risk reduction. A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m(2); 68 % women, and 45 % members of minority groups. Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

186. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. BACKGROUND: In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative. We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose (...) disease was uncontrolled with metformin. METHODS: In this comparative, parallel, randomised, open-label trial, metformin-treated people aged 35-70 years with glycated haemoglobin A(1c) (HbA(1c)) of 7-11%, diagnosis of type 2 diabetes for at least 6 months, and body-mass index of 25-45 kg/m(2) were recruited from 17 countries. Participants were randomly assigned (1:1) to 24-week treatment with insulin glargine (titrated from an initial subcutaneous dose of 0·2 units per kg bodyweight to attain fasting

Lancet2012

187. Exenatide twice-daily in combination with insulin (Byetta) - as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes

Exenatide twice-daily in combination with insulin (Byetta) - as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes

Scottish Medicines Consortium2012

188. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study 22210563 2012 01 25 2012 06 12 2016 12 15 1935-5548 35 2 2012 Feb Diabetes care Diabetes Care Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. 252 (...) -8 10.2337/dc11-1107 To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes. Patients were randomized to subcutaneous (SC) EQW 2.0 mg + oral placebo (n = 248), MET 2,000 mg/day + SC placebo (n = 246), PIO 45 mg/day + SC placebo (n = 163), or SITA 100 mg/day + SC placebo (n = 163) for 26 weeks. MET and PIO therapies

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

189. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis

Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY (...) , Zhang SH CRD summary The review found that there was insufficient evidence to determine whether metformin or thiazolidinediones were superior for the treatment of polycystic ovary syndrome. Considering the poor quality of included trials and substantial variation, the authors' cautious conclusions are appropriate and likely to be reliable. Authors' objectives To compare the efficacy and safety of insulin-sensitising drugs such as metformin and thiazolidinediones for the treatment

DARE.2012

190. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis

Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis Praharaj SK, Jana AK, Goyal N, Sinha VK CRD summary The review concluded that metformin significantly reduced olanzapine-induced weight gain in the short term. There was a significant reduction in body mass index, but the reduction in waist (...) circumference was not significant. Potential review limitations and uncertain study quality make the reliability of the authors’ conclusions unclear. Authors' objectives To evaluate the effectiveness of metformin for reducing or preventing olanzapine-induced weight gain. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for publications in English; search terms were reported. Search dates were not explicitly stated, but the included studies were published between

DARE.2012

191. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study 21733058 2011 10 28 2012 01 16 2013 11 21 1463-1326 13 12 2011 Dec Diabetes, obesity & metabolism Diabetes Obes Metab Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week (...) , randomized, double-blind, active-controlled, parallel-group study. 1088-96 10.1111/j.1463-1326.2011.01463.x To assess the efficacy and safety of adding alogliptin versus uptitrating pioglitazone in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone. In this randomized, double-blind, active-controlled, parallel-group study, patients with type 2 diabetes and A1c ≥7.0 and ≤10.0% on metformin (≥1500 mg or maximum tolerated dose; Met) and pioglitazone 30 mg (Pio30

EvidenceUpdates2012

192. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Lamanna C, Monami M, Marchionni N, Mannucci E CRD summary This review concluded that the evidence seemed to exclude any overall harmful effect of metformin on cardiovascular risk (...) and suggested a possible benefit versus placebo/no treatment. Limitations with the included evidence and a lack of reporting of some aspects of the review process limit the reliability and generalisability of the results. The cautious conclusion and recommendations for research seem appropriate. Authors' objectives To assess the effects of metformin on the incidence of cardiovascular events and mortality. Searching MEDLINE, EMBASE and The Cochrane Library were searched for articles published in English from

DARE.2012

193. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff (...) Diabetes Model analysis Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of saxagliptin and metformin, compared with sulphonylurea

NHS Economic Evaluation Database.2012

194. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis

Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis Poolsup N, Suksomboon N, Setwiwattanakul W CRD summary This review concluded (...) that different antidiabetic agents in combination with metformin had similar effects in reducing glycated haemoglobin levels in type 2 diabetes patients, previously treated with metformin monotherapy. This was a well-conducted review; the conclusions reflect the evidence shown, but limitations of the evidence base mean that the recommendation for further research is warranted. Authors' objectives To evaluate the efficacy of combination therapy of metformin with any antidiabetic agents in the treatment

DARE.2012

195. Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis

Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis Al-Shareef MA, Sanneh AF, Aljoudi AS CRD summary This review concluded that there was limited and unconvincing evidence (...) to suggest that metformin can improve glycaemic control in children and adolescents with type 2 diabetes. These conclusions and the authors' recommendations for further research appear justified and reliable. Authors' objectives To assess the clinical effectiveness of metformin monotherapy versus other treatments for type 2 diabetes in children and adolescents. Searching The Cochrane Library, MEDLINE, EMBASE and IPA were searched up to May 2008 with no language restrictions. Four clinical trial registers

DARE.2012

196. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis

Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis Bouza C, Lopez-Cuadrado T, Gutierrez-Torres LF, Amate J CRD summary The authors concluded (...) that short-term use of metformin in combination with lifestyle modification was relatively effective and safe for reducing body mass index and hyperinsulinaemia among obese adolescents without related morbidity. These conclusions reflect the evidence presented but cannot be considered reliable due to limitations of the evidence base. Authors' objectives To assess the efficacy and safety of metformin for treatment of overweight and obesity in adolescents without related morbidity. Searching MEDLINE

DARE.2012

197. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses (...) and trial sequential analyses Hemmingsen B, Lundby L, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T CRD summary This review found no evidence of a difference in risk of death between patients treated with metformin and insulin and those given insulin alone. Some significant differences were found for other outcomes. The authors' conclusions reflect the limitations of the evidence and appear reliable. Authors' objectives To compare the benefits and harms of metformin and insulin

DARE.2012

198. Randomised controlled trial: Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes

Randomised controlled trial: Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes Article Text Therapeutics Randomised controlled trial Metformin is not significantly different from insulin

Evidence-Based Medicine (Requires free registration)2012

199. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Stevens RJ, Ali R, Bankhead CR (...) , Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR CRD summary The review concluded that there was no statistically significant beneficial effect of metformin on cancer or mortality outcomes compared with other drugs, placebo or usual care. The review was generally well conducted. The authors noted shortcomings in the quality of the evidence base

DARE.2012

200. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G CRD summary The review concluded that metformin appeared to reduce subsequent cancer risk, especially risk (...) of pancreatic and colorectal cancer, in patients with diabetes but sulphonylurea did not. The uncertain quality of the evidence base, differences across studies and potential for biases and confounding limit the reliability of the pooled results and hence the authors' conclusions. Authors' objectives To determine the association of metformin and sulphonylurea with the risk of cancer in patients with type 2 diabetes. Searching MEDLINE was searched to May 2011 for articles published in English. Search terms

DARE.2012